Loan for Acquisition of Shire plc in Ireland by Takeda Pharmaceutical Company Limited
Supporting Overseas M&A of a Japanese Company in the Pharmaceutical Industry
- Region: Europe
- Overseas Investment Loans
The Japan Bank for International Cooperation (JBIC; Governor: Tadashi Maeda) signed today a loan agreement with Takeda Pharmaceutical Company Limited (Takeda), amounting up to USD3.7 billion (JBIC's portion), to finance part of the funds required for acquiring Shire plc (Shire) in Ireland. The total amount required for acquisition is approximately GBP46 billion. The loan is co-financed by private financial institutions, bringing the total co-financing amount to USD15.7 billion equivalent.
Shire has strength in pharmaceuticals for rare diseases and plasma-derived therapies*1
, the demand for which is expected to grow. This biopharmaceutical company also has multiple leading brands and new drug pipelines for digestive and central nervous systems. Through the acquisition, Takeda not only aims to strengthen two focus areas, namely, gastroenterology and neuroscience, but also intends to establish a leading position in pharmaceuticals for rare diseases and plasma-derived therapies, which can accelerate transformation to a global R&D-driven pharmaceutical company headquartered in Japan. In addition, Shire has a large sales proportion in the U.S. market, which is the largest market in the world and expected to continue to grow at a high rate. The acquisition thus makes it possible to gain further driving force for growth overseas and is expected to make Takeda one of the top 10 pharmaceutical companies in the world based on sales.
This loan supports overseas business deployment of Takeda by providing necessary long-term foreign currency funds for M&A by the Japanese company. Thereby, it will back up its overseas expansion of existing business as well as new business deployment, and contribute to maintaining and strengthening the international competitiveness of Japanese industries.
Supporting overseas M&As by Japanese companies is one of the key focus areas identified in JBIC's Third Medium-Term Business Plan for FY2018-2020 . As Japan's policy-based financial institution, JBIC will continue to support overseas M&A activities of Japanese companies and their overseas business expansion in collaboration with private financial institutions.
Products manufactured by separating and refining from human blood plasma each type of plasma protein necessary for treatment.